Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Biopharmaceuticals stock Gilead Sciences ( GILD 3.08%) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...

Shares of Gilead Sciences (NASDAQ:GILD) dropped 2.8% Monday morning after reports emerged that U.S. Health and Human Services ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...